cell-reprogramming
(2)
Tune Therapeutics
Tune Therapeutics is a genetic-medicine company building tools to turn genes up or down without cutting DNA. Its TEMPO epigenetic-editing platform tunes gene expression the way a sound engineer rides a fader - reversible, programmable, and precise. Spun out of Duke's Gersbach Lab, Tune raised over $175M in Series B financing in January 2025 and is running first-in-human trials of TUNE-401, an epigenetic silencer for chronic hepatitis B, with the larger ambition of editing the genome's software to extend human healthspan.
I Peace, Inc.
I Peace, Inc. is a Palo Alto- and Kyoto-based biotech that mass-manufactures clinical-grade induced pluripotent stem cells (iPSCs) using a proprietary automated, closed-cassette platform. Founded in 2015 by Koji Tanabe - a co-author of the world's first human iPSC paper from Shinya Yamanaka's Nobel Prize-winning lab - the company operates as a CDMO supplying GMP-grade iPSCs to pharmaceutical companies, biotechs, and research institutions, and offers personal iPSC banking and longevity services that aim to make cell therapy affordable and accessible.